Gamida Cell Stock Jumps Over 100% on FDA Approval
Key PointsGamida develops blood cell therapies for blood cancer and hematological diseases.On April 17, 2023, Gameda received its first FDA approval for Omisirge, a treatment to lower infections for blood cancer patients who’ve had a bone marrow transplant.The company hopes to garner up to 25% market share of patients with hematologic malignancies in 2026.Shares of Gameda Cell have a 10% short interest.5 stocks we like better than Gamida CellGamida Cell Ltd. (NASDAQ:GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight b...